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Abstract
Background: Mesenchymal stem cells (MSCs) have emerged as a promising option to treat articular chondral
defects and early OA stages. However, their potential and limitations for clinical use remain controversial. Thus, the
aim of this systematic review was to examine MSCs treatment strategies in order to summarize the current clinical
evidence for the treatment of cartilage lesions and OA.
Methods: A systematic review of the literature was performed on the PubMed database using the following string:
“cartilage treatment” AND “mesenchymal stem cells”. The filters included publications on the clinical use of MSCs
for cartilage defects and OA in English language up to 2015.
Results: Our search identified 1639 papers: 60 were included in the analysis, with an increasing number of
studies published on this topic over time. Seven were randomized, 13 comparative, 31 case series, and 9
case reports; 26 studies reported the results after injective administration, whereas 33 used surgical
implantation. One study compared the 2 different modalities. With regard to the cell source, 20 studies
concerned BMSCs, 17 ADSCs, 16 BMC, 5 PBSCs, 1 SDSCs, and 1 compared BMC vs PBSCs.
Conclusions: The available studies allow to draw some indications. First, no major adverse events related to
the treatment or to the cell harvest have been reported. Second, a clinical benefit of using MSCs therapies
has been reported in most of the studies, regardless of cell-source, indication or administration method. Third,
young age, lower BMI, smaller lesion size for focal lesions and earlier stages of OA joints, have been shown
to correlate with better outcomes, even though the available data strength doesn’t allow to define clear
cutoff values.
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Background
Articular cartilage lesions are a debilitating disease,
often resulting in fibrillation and subsequent degrad-
ation of the surrounding articular surface, possibly in-
volving the subchondral bone as well, thus favoring
the development of osteoarthritis (OA). OA affects up
to 15 % of the adult population and represents the
second greatest cause of disability worldwide [1], with
a massive impact on society both in terms of quality
of life for the individuals and high costs for the
healthcare system [2]. Several approaches have been
proposed for the management of cartilage degener-
ation, ranging from pharmacological to surgical
options, aimed at reducing symptoms and restoring a
satisfactory knee function [3, 4]. However, none of
them has clearly shown the potential of restoring
chondral surface and physiological joint homeostasis
in order to prevent OA, which in the final stage often
requires prosthetic replacement.
Among the solutions proposed to delay the need for
metal resurfacing of the damaged articular surface, mes-
enchymal stem cells (MSCs) have recently emerged as a
promising option to treat articular defects and early OA
stages [5]. MSCs are multipotent progenitor cells that
can differentiate into selected lineages including chon-
drocytes, with capability of self-renewal, high plasticity,
and immunosuppressive and anti-inflammatory action
[6, 7]. Moreover, Caplan and colleagues [8] recently
underlined that these cells, derived from perivascular
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cells called “pericytes”, have a key role in the re-
sponse to tissue injuries not just by differentiating
themselves, but also by inducing repair/regeneration
processes at the injury site through the secretion of
several bioactive molecules [9]. In light of these prop-
erties, MSCs represent an excellent candidate for cell
therapies and their healing potential has been ex-
plored also in terms of cartilage tissue regeneration
and OA processes modulation [6]. The first investiga-
tions involved MSCs derived from bone marrow,
which have been applied either as a cell suspension
after being expanded by culture (BMSCs), or used as
a simple bone marrow concentrate (BMC), thanks to
their relative abundance [6]. Despite an extensive pre-
clinical research and promising clinical results, some
drawbacks related to the cell harvest and culture led
to the development of different alternative options,
with stem cells derived from adipose tissue (ADSCs),
synovial tissue (SDSCs), and peripheral blood (PBSCs)
[10, 11]. Besides these sources already explored and
reported in the clinical use, cells derived from fetal
tissues are being currently investigated at preclinical
level [12]. Although numerous advancements have
been made, the understanding of MSCs mechanism of
action as well as their potential and limitations for
the clinical use remain controversial. Many questions
are still open on the identification of patients who
might benefit more from this kind of treatment, as
well as the most suitable protocol of administration
(no. of cells, concentrated or culture-expanded, best
harvest source, etc.).
Based on these premises, the aim of this systematic re-
view was to examine the literature on MSCs treatment
strategies in the clinical setting, in order to summarize
the current evidence on their potential for the treatment
of cartilage lesions and OA.
Materials and methods
A systematic review of the literature was performed on
the PubMed database by two independent reviewers
using the following string: “cartilage treatment” AND
“mesenchymal stem cells”. The filters included publica-
tions on the use of MSCs for cartilage defects and OA in
the clinical field and in English language, published from
2000 to the end of 2015. Articles were first screened by
title and abstract. Subsequently, the full texts of the
resulting articles were screened and those not reporting
clinical results of MSCs for cartilage and OA treatment
were excluded. The reference lists of the selected articles
were also screened to obtain further studies for this
review.
Results
Our search identified 1639 papers after the screening
process, 60 were included in the analysis (Fig. 1), which
showed an increasing number of studies published on
this topic over time (Fig. 2). Among the 60 selected
studies, 7 were randomized, 13 comparative, 31 case
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Fig. 1 Scheme of research methodology
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series, and 9 case reports; 26 studies reported the results
after injective administration, whereas 33 used surgical
implantation. One study compared the two different mo-
dalities. With regard to the cell source, 20 studies con-
cerned BMSCs, 17 ADSCs, 16 BMC, 5 PBSCs, 1 SDSCs,
and 1 compared BMC versus PBSCs. While all the in-
cluded studies are summarized in detail in Table 1 ac-
cording to cell source and treatment strategy, the most
relevant findings will be discussed in the following
paragraphs.
BMSCs
An increasing number of papers have been focused
on this cell source in the past few years, both as
BMSCs and BMC. Cultured BMSCs and BMC differ
for composition, since adult bone marrow contains
heterogeneous blood cells at various differentiation
stages [13]. Thus, the harvest includes plasma, red
blood cells, platelets, and nucleated cells, a small frac-
tion of which contains adult MSCs that can be iso-
lated through culture expansion [14]. However, even
if not expanded, the heterogeneity of cell progenitor
types in BMC might positively influence tissue regen-
eration [15]. Moreover, cell culture not only offers a
higher number of cells but also presents high costs
and some regulatory problems, since these products
might be considered as pharmacological treatments by
regulatory agencies. Thus, one-step techniques using
BMC for the delivery of autologous cells in a single
time are gaining increasing interest in the clinical set-
ting. Besides these considerations, positive findings
are leading the research towards the use of both cell-
based strategies.
Cultured BMSCs: injective treatment
In 2008, Centeno and colleagues [16] first reported the
promising clinical and MRI improvements at early
follow-up after single intra-articular (i.a.) injection of au-
tologous cultured BMSCs in a patient with knee degen-
erative cartilage disease, and similar findings at short
term were later shown also by the groups of Davatchi
[17], Emadedin [18], and Sol Rich [19]. Orozco et al.
confirmed a rapid and progressive clinical improvement
of knee OA in the first 12 months [20], which was main-
tained at 24-month follow-up, together with improved
cartilage quality at MRI [21]. Finally, Davatchi et al. [22]
updated their report, showing gradual mid-term deteri-
oration of the outcomes in advanced OA.
Among comparative studies, Lee et al. [23] tested two
administration strategies for focal knee cartilage defects
and found no differences either by using BMSCs im-
plantation under periosteum flap or microfractures
(MFX) plus BMSCs i.a. injection, thus endorsing the less
invasive approach.
Three randomized controlled trials (RCTs) have also
been published. Wong et al. [24] treated knee unicom-
partmental OA with varus malalignment by combined
high tibial osteotomy (HTO) and MFX. Patients ran-
domly received post-operative i.a. injection of BMSCs-
hyaluronic acid (HA) or HA alone as control. Both
groups improved their scores, but BMSCs produced bet-
ter clinical and MRI outcomes. Vangsness et al. [25] ad-
ministered a single i.a. injection in patients after medial
partial meniscectomy. Patients were randomized in two
treatment groups (low- or high-dose allogeneic cultured
BMSCs with HA) and a control group (HA-only). Both
treatment groups showed improved clinical scores versus
control, and MRI showed signs of meniscal volume
Fig. 2 The systematic research showed an increasing number of clinical studies published over time
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Table 1 Details of the 60 clinical trials identified by the systematic review focusing on MSCs use for the treatment of cartilage pathology




Int Journal of Rheum
Disease
Case series IA injection Previous study update Knee OA 3 60 months Still significant improvement at




RCT IA injection Allogeneic BMSCs Knee OA 15 BMSCs
15 HA
12 months Significant better functional and
cartilage quality improvements in
MSCs group vs. control
Sol Rich [18] 2015
J Stem Cell Res Ther
Case series IA injection Knee OA 12 24 months Excellent clinical and quantitative
MRI outcome measures at 2 years
Vangsness [25] 2014
JBJS Am
RCT IA injection Allogeneic BMSCs
After medial
meniscectomy
Knee OA 18 low-dose MSCs +
HA
18 high-dose MSCs +
HA
19 HA
24 months Knee pain improvement and
evidence of meniscus




Case series IA injection Previous study update Knee OA 12 24 months Pain improvement at 12 months
maintained at 24 months.
The quality of cartilage further
improved at MRI at 24 months
Wong [24] 2013
Arthroscopy
RCT IA injection Comb HTO + MFX and
post-op injection
Knee OA 28 BMSCs + HA
28 HA
24 months BMSCs i.a. injection produced
superior clinical and MRI
outcomes at 24 months
Ricther [35] 2013
Foot & Ankle




25 24 months No adverse events.
Clinical scores improvement
Positive findings at histology
Orozco [22] 2013
Transplantation
Case series IA injection Knee OA 12 12 months No safety issues. Rapid and
progressive clinical improvement
at 12 months





Comparative IA injection Knee cartilage
defects
35 MFX + BMSCs + HA
35 BMSCs + periosteal
patch
24 months MFX + BMSCs + HA had
comparable results vs. BMSCs +




Case series IA injection Knee OA 6 12 months No local or systemic adverse
events.
Decreased pain, improved
function and walking distance
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2 31 months Significant clinical improvement
Good filling, tissue stiffness, and
integration at 2nd look
Davatchi [17] 2011
Int J Rheum Dis















Table 1 Details of the 60 clinical trials identified by the systematic review focusing on MSCs use for the treatment of cartilage pathology (Continued)
Haleem [28] 2010
Cartilage




5 12 months 5/5 symptoms improvement
Complete defect filling and
surface congruity with native
cartilage in 3/5 at MRI
Nejadnik [34] 2010
AJSM
Comparative Surgical delivery BMSCs + periosteal flap Knee cartilage
defects
36 ACI
36 BMSCs + periosteal
flap
24 months Comparable improvement in
quality of life, health, and sport
activity. M better than F, older
than 45 years lower improvement
only in ACI group.
Centeno [16] 2008
Pain Physician
Case report IA injection Knee cartilage
defects
1 IA BMSCs + 2 weekly
platelet lysate IA
injections
24 months Improvement of range of motion
and pain scores. Significant









1 12 months Hyaline-like tissue regeneration,
improvement in clinical
symptoms and return to previous
activity level
Wakitani [31] 2007
J Tissue Eng Regen
Med





3 17–27 months Improvement in clinical
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2 5 years Short-term clinical improvement,





Comparative Surgical delivery Collagen gel sheet +
periosteum
Knee OA 12 BMSCs + HTO
12 cell-free control +
HTO
16 months Comparable clinical outcomes,
but better arthroscopic and
histological score in cell-
transplanted group
BM Concentrate Gobbi [47] 2015
Cartilage







3 years Significant scores improvement in
both groups.
Better IKDC subj for BMC. MACI:
trochlea better than patella; BMC:
site n.s.




Case series Surgical delivery MAST
HA matrix
OLTs and ankle OA 56 36 months Clinical outcome improvement at
12 months, further increase at
24 months and lowering trend at
36 months















Table 1 Details of the 60 clinical trials identified by the systematic review focusing on MSCs use for the treatment of cartilage pathology (Continued)
Buda [39] 2015
Cartilage





5 24 months Clinical improvement at 2 years.
3 patients back to sports.




Buda R [43] 2015
Int Orthop
Comparative Surgical delivery MAST
HA matrix + PRF
OLTs 40 ACI
40 BMC
48 months ACI and MAST was equally
effective for the treatment of OLT.
MAST preferred for the 1 step
procedure, and lower costs
Gobbi [50] 2014
AJSM




25 3 years Significant scores improvement
Older than 45 and smaller or
single lesions showed better
outcomes.
Good implant stability and
complete filling at MRI.
Cadossi [44] 2014
Foot Ankle Int
RCT Surgical delivery MAST
HA matrix
OLTs 15 BMDCs + HA + PEMF
15 BMDCs + HA
12 months Biophysical stimulation started
soon after surgery aided patient
recovery leading to pain control
and a better clinical outcome
with these improvements lasting
more than 1 year after surgery
Buda [41] 2014
Joints
Case series Surgical delivery MAST
HA/collagen powder
matrix + PRF
OLTs 41 BMAC + HA + PRF
23 BMAC + collagen
powder + PRF
53 months Significant clinical improvement,








54 5 years Improvement in clinical scores in 52/
54 patients without complications








OLTs 49 24–48 months Good clinical results at
24 months, then significant
decrease at 36 and 48 months. T2
mapping similar to native hyaline




Case series Surgical delivery MAST
HA matrix
OLKs 30 29 months Good clinical outcome
osteochondral regeneration at
control MRI and biopsies
Gigante [48] 2012
Arhtroscopy Technique





1 24 months Pain free at 6 months, still
asymptomatic at 24 months









5 12 months Patients asymptomatic
Nearly normal arthroscopic
appearance and satisfactory repair














Table 1 Details of the 60 clinical trials identified by the systematic review focusing on MSCs use for the treatment of cartilage pathology (Continued)
Giannini [42] 2010
Injury
Comparative Surgical delivery MAST
HA matrix + PRF
OLTs 10 ACI open
46 arthroscopic MACT
25 arthroscopic MAST
36 months Similar clinical improvement
among groups.
Good restoration of the
cartilaginous layer with hyaline-
like characteristics at MRI and
histology
Varma [36] 2010
J Indian Med Assoc
Comparative IA injection Augmentation to
debridement
Knee OA 25 Debridement + BMC
25 Debridement alone
6 months BMC: higher improvement in




Case series Surgical delivery MAST
HA matrix + PRF
OLKs 20 24 months Significant clinical improvement
at 12 and 24 months. Associated
procedures delayed recovery.
Satisfactory MRI findings in 80 %
of patients
Giannini [37] 2009
Clin Orthop Rel Res
Case series Surgical delivery MAST
HA matrix or collagen
powder + PRF
OLTs 48 24 months Clinical improvement
Regenerated tissue in various
degree of remodeling, none had
complete hyaline-like features at
histology
PBSCs Fu [55] 2014
Knee






1 7.5 years Patient returned to competitive
kickboxing
Smooth surface 8 months after
surgery
Significant clinical and MRI
improvements
Turajane [53] T 2013
J Med Assoc Thai
Case series IA injection PBSCs + GFs addition/
preservation + HA +
microdrilling




RCT IA injection Subchondral drilling
PBSCs + HA vs. HA
5 IA injections post-op




25 drilling + (PBSCs +
HA)
25 drilling + HA
2 years Comparable significant clinical
improvement for both groups
PBSCs + HA had both MRI and









52 6 years No adverse events
Improvement in all clinical scores
at 12 months. Poor outcomes in
2 patients at 12 months
At 72 months minor deterioration
in 2 more patients
Saw [52] 2011
Arthroscopy
Case series IA injection Subchondral drilling +





No adverse events hyaline
cartilage regeneration at histology
BMC vs. PBSCs Skowronski [77] 2013
Orthop Traumatol
Rehabil




5 years Superior results in PBSCs group:
good cartilaginous surface and
integration. Slight clinical scores















Table 1 Details of the 60 clinical trials identified by the systematic review focusing on MSCs use for the treatment of cartilage pathology (Continued)
SDSCs Sekiya [76] 2015
Clin Orthop Relat Res




10 48 months Significant clinical improvement
Positive findings at MRI, and
hyaline like in 3/4 at histology





SVF on FG scaffold vs.
PRP-SVF injection
Isolated focal
defects in knee OA
20 SVF-FG
20 SVF-PRP
28.6 months Significant improvement in both
groups. Better clinical results at
final f-up and 2nd look
appearance at 12 months for SVF-
FG. No. of cells correlated with
outcomes only for injective group
Kim [72] 2015
Osteoarthritis Cartilage
Case series Surgical delivery Subcutaneous fat
SVF + FG scaffold
Isolated focal
defects in OA knee
20 27.9 months Significant clinical and MRI scores
improvement




Case series IA injection Subcutaneous fat
SVF




Follow-up at 12 months: 63 %
patients had ≥75 % score
improvement
91 % patients had ≥50 % score
improvement




RCT Surgical delivery Subcutaneous fat




40 MFX + SVF-FG
40 MFX
27.4 months KOOS pain and symptoms better
for SVF vs. control
2nd look: complete coverage 65
vs. 45 %
SVF better MRI scores
Kim [73] 2015
AJSM
Case series Surgical delivery Subcutaneous fat
SVF + FG
Isolated Focal
defects in OA knee
49 26.7 months 74.5 % good/excellent results
Patient age >60 years or lesion




Case series IA injection Cultured subcutaneous
Phase I: low dose
(1.0 × 107) vs. mid-dose
(5.0 × 107) vs. high
dose (1.0 × 108)
Phase II: 18 patients re-
ceived only high dose
Knee OA Phase I: 9
Phase II: 18
6 months High-dose was more effective for
knee function improvement
MRI: decreased defect size and
improved cartilage volume








OLTs 24 marrow stim + SVF
26 marrow stimulation
21.9 months All clinical and MRI scores in SVF
group improved significantly with
respect to marrow stimulation
alone SVF gave better outcomes
for patients older than 46.1 years,
lesion size >152.2 mm2, or in














Table 1 Details of the 60 clinical trials identified by the systematic review focusing on MSCs use for the treatment of cartilage pathology (Continued)
Kim [71] 2014
AJSM
Comparative Surgical delivery Subcutaneous fat
SVF local adherent vs.
SVF + FG
Isolated focal
defects in OA knee
17 FG
37 scaffold-free
28.6 months Both comparable clinical
improvement
2nd look arthrosocopy at
12.3 months f-up: better ICRS
scores for FG group
Bui [62] 2014
Biomed Res Ther
Case series IA injection Subcutaneous fat
SVF + PRP
Knee OA 21 8.5 months Significant clinical scores
improvement. No side effects.
MRI: increased cartilage thickness
Koh [70] 2014
AJSM
Case series Surgical delivery Subcutaneous fat
SVF
Isolated focal
defects in knee OA
35 26.5 months Clinical improvement
76 % abnormal repair tissue at
2nd look arthroscopy
(12.7 months f-up)
Better outcomes if size <5.4 cm2
and/or BMI < 27.5
Koh [74] 2014
Arthroscopy
RCT IA injection Subcutaneous fat
HTO + PRP vs. HTO +
PRP + SVF
Knee OA 23 HTO + PRP + SVF
21 HTO + PRP
24 months SVF produced better
improvement of KOOS pain and
symptoms and VAS pain





Case series IA injection Subcutaneous fat SVF
+ PRP
OA (various joints) 91 26.7 months SVF/PRP injections are safe









30 MFX + SVF
21.8 months Clinical improvement both groups
SVF group better results, especially
applied to Tegner score
Large lesion and/or subchondral




Case series IA injection Subcutaneous fat
SVF + PRP
Knee OA 30 24 months Significant clinical improvement
14/16 (87.5 %) of 2nd look
arthroscopy within 24 months
improved or maintained cartilage
status.









Knee OA 18 24 months function and pain improvement.
Womac and MRI correlate with
cell no.














SVF performed better in
<55 years and OA≤ 3 (ICRS)
Pak [60] 2011
J Med Case Rep
Case report IA injection Subcutaneous fat
SVF + PRP + low dose
dexamethasone
Knee OA 2 3 months Clinical improvement















increase at 24 months. Finally, Vega et al. [26] random-
ized two treatment groups for knee OA: a significantly
greater improvement was shown after a single allogeneic
BMSCs injection compared to control HA.
Cultured BMSCs: surgical delivery
Adachi et al. [27] observed cartilage and bone regener-
ation in a biopsy after cultured BMSCs implantation on
hydroxyapatite-ceramic scaffold for osteochondral knee
lesion (OLK). Haalem et al. [28] implanted BMSCs on a
platelet fibrin glue (FG) scaffold, showing significant im-
provement and complete MRI filling of the cartilage de-
fect. Kasemkijwattana et al. [29] seeded cells on a
collagen scaffold with positive results in two traumatic
knee lesions. Similarly, Kuroda et al. [30] had good re-
sults implanting BMSCs on collagen membrane with
periosteum coverage in a judo-player knee, with hyaline-
like tissue at a 12-month histology evaluation. Wakitani
et al. used the same technique with positive findings also
for patellofemoral lesions [31], stable at mid-term
follow-up [32]. They also performed a comparative
evaluation of this technique for focal defects in OA
knees: two groups were treated with HTO, with or with-
out BMSCs augmentation [33]. BMSCs-group showed
better histology, but clinical scores comparable to the
cell-free group. Nejadnik et al. compared BMSCs im-
plantation with first-generation ACI in two groups of pa-
tients and observed comparable benefits [34].
Finally, Richter et al. [35] investigated the outcomes
offered by BMSCs onto a collagen matrix for chondral
ankle lesions, confirming no complications and a prom-
ising clinical improvement at 24 months of follow-up.
BMC: injective treatment
A single study by Varma et al. [36] reported promising
results with BMC injection after arthroscopic debride-
ment for knee OA, with increased benefits compared to
debridement alone.
BMC: surgical delivery
The group of Giannini published several studies of
scaffold-associated BMC implantation in knee and ankle
joint defects. In their first study [37], they showed clin-
ical and MRI improvements at 24 months after BMC
implantation into collagen powder or HA matrix for
osteochondral lesions of the talus (OLTs). Later [38],
they reported a significant worsening between 24 and
48 months of follow-up, but the final result was still sat-
isfactory compared to the basal level. Patients with lon-
ger symptoms before surgery had worse clinical
outcomes. They also observed no degeneration progres-
sion at 24 months in five hemophilic ankle lesions [39],
and similar results were confirmed in a larger group of
patients treated for OLTs or ankle OA defects [40]. Also,
this study showed a worsening trend after 24 months
with a higher failure rate, which underlined the influence
of OA degree and patient BMI. Moreover, a further
study by Buda et al. [41] confirmed a similar trend of
gradual worsening up to 72 months after scaffold-
assisted BMC implantation.
Giannini et al. [42] also performed comparative evalu-
ations: positive and similar clinical outcomes were found
in three groups of patients treated with one-step BMC-
HA matrix implantation versus open ACI or arthro-
scopic MACT for OLTs at 36 months of follow-up.
These results were later confirmed at 48 months after
collagen scaffold implantation, seeded either with BMC
or cultured chondrocytes, with better tissue quality at
MRI for the BMC group [43]. Moreover, a RCT by
Cadossi et al. [44] highlighted that biophysical stimula-
tion with pulsed electromagnetic fields (PEMFs) might
improve the results at 12 months after collagen matrix-
BMC implantation for OLTs.
Matrix-assisted BMC implantation was also investi-
gated for the treatment of OLKs. The promising results
using BMC on HA matrix were first reported by Buda
et al. at short-term follow-up, with positive MRI and
histology findings [45, 46], and then confirmed by Gobbi
et al. [47], who observed superior outcomes using BMC
instead of chondrocytes for the treatment of large patel-
lofemoral defects. Similar results were obtained also by
seeding BMC on collagen scaffolds: Gigante et al. [48]
used BMC-enhanced AMIC technique with positive
short-term clinical results, but limited tissue quality at
histology [49], and Gobbi et al. [50] observed hyaline ap-
pearance and better short-term improvement in patients
younger than 45 years and with single and smaller le-
sion. Finally, Skowronski et al. [51] documented stable
mid-term outcomes after the treatment of large chondral
lesions.
PBSCs
The possibility of using autologous PBSCs obtained by
culture expansion from a venous sample was first intro-
duced by Saw et al. [52], who treated chondral knee le-
sions with subchondral drilling and five postoperative
i.a. injections of PBSCs and HA, reporting no adverse re-
actions and positive histological findings. Turajane and
colleagues [53] showed short-term clinical improvement
using the same technique in early knee OA patients.
Later, the group of Saw [54] also performed a RCT, doc-
umenting comparable clinical outcomes at 24 months,
but better MRI and histological evaluations versus HA
control.
With regard to surgical application, Fu et al. [55] re-
ported optimal results at 7.5 years in a lateral trochlea
lesion treated with patellar realignment plus periosteum-
covered PBSCs implantation in a kick boxer, and
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Skowronski et al. [56] implanted PBSCs with a collagen
membrane in a group of patients, reporting a stable im-
provement up to 72-month follow-up.
ADSCs
ADSCs present a lower chondrogenic potential when
compared with BMSCs [57]. Nonetheless, they can be
obtained from liposuction, a simple and cheap proced-
ure, and their clinical use is rapidly increasing, thanks to
their easy availability and abundance [10]. Whereas the
use of cultured cells has rarely been reported, the pre-
ferred technique involves cell harvest, collagenase diges-
tion, and isolation of the stromal vascular fraction (SVF),
a heterogeneous cell population that, among pre-
adipocytes and immune cells, also includes ADSCs [58].
Injective treatment
Jo et al. [59] published the only available study on cul-
tured ADSCs, applied at different doses: their prelimin-
ary clinical data showed no adverse events, and a
clinical-MRI improvement at 6 months after injecting
the highest dose.
Most of the literature focused instead on SVF. Regard-
ing knee OA, Pak et al. [60] first obtained a promising
clinical improvement 3 months after i.a. injection of sub-
cutaneous SVF with HA, dexamethasone, and PRP in a
patient. Later, they [61] confirmed safety and effective-
ness of SVF injections in a larger cohort of patients
treated into different joints. Bui et al. [62] also reported
short-term clinical and MRI improvement after injection
of SVF and PRP. However, the group of Koh was the
main investigator of SVF use, starting from the infrapa-
tellar fat pad source, in a case–control study [63]: all pa-
tients underwent debridement and the treatment group
received an additional SVF-PRP injection. No major ad-
verse events and a tendency for better outcomes were
observed in the SVF group. The improvement was con-
firmed at 24 months in a further study [64]. The number
of injected cells correlated with both clinical and MRI
outcomes, while SVF had lower effects on the final stage
OA. Later, the same group began to process subcutane-
ous fat with an analogous technique. They treated knee
OA in elderly patients with arthroscopic lavage and
SVF-PRP injection [65]: clinical improvement was ob-
tained both at 12 and 24 months, and positive findings
were reported at second look evaluation. Moreover, SVF
injections significantly improved the benefits of high tib-
ial osteotomy (HTO) for symptomatic varus knee, com-
pared to control (HTO and PRP-only), both at clinical
and second look evaluation [66].
Michalek et al. [67] administered single-dose SVF in-
jections to the largest available group of patients, report-
ing no treatment-related adverse events and gradual
clinical improvement between 3 and 12 months, with a
slower recovery for obese and higher OA degrees.
Finally, the group of Koh also investigated SVF use in
the ankle joint: Kim et al. injected SVF after marrow
stimulation in two comparative studies, and observed
higher clinical and MRI improvement both for ankle OA
[68] or OLTs [69], compared to surgery alone. The bene-
fit was greater for younger patients with smaller lesions,
but the treatment was effective even in older patients.
Surgical delivery
Koh et al. [70] reported a significant clinical improve-
ment 2 years after a scaffold-free SVF implantation for
focal chondral lesions in OA knees, but abnormal repair
tissue was observed in most cases at second look evalu-
ation. In a subsequent study, the association with FG as
scaffold significantly improved tissue quality, even
though clinical results remained similar to SVF alone
[71]. Later, they reported positive short-term results and
correlation with MRI findings after SVF-FG implantation
for OA [72]. Furthermore, a larger prospective study
confirmed good/excellent results in 75 % patients at
24 months [73]. Interestingly, older age, higher BMI, and
larger defect size were negative predictors in all these
studies. SVF-FG augmentation also improved the out-
come versus MF alone in an RCT, despite comparable
histology findings [74].
Finally, a study on matched-paired groups found com-
parable clinical results but better ICRS macroscopic
scores at 12 months for SVF surgical implantation versus
injective delivery, whereas at the further follow-up, a sig-
nificant clinical superiority was also obtained for surgical
SVF delivery [75].
SDSCs
SDSCs are a promising source of stem cells for cartilage
tissue engineering, thanks to the greatest chondrogenic
and lowest osteogenic potential among MSCs [57].
Sekiya et al. [76] reported promising results up to mid-
term follow-up using SDMSCs scaffold-free implantation
into single knee cartilage defects, with ¾ biopsies show-
ing hyaline cartilage.
Comparative studies
Skowronski et al. [77] performed the only clinical com-
parative study among stem cell types showing superior
results with PBSCs rather than BMC under a collagen
membrane for OLKs at 5-year follow-up.
Discussion
This systematic research highlighted that the use of mes-
enchymal precursors as a biological approach to treat
cartilage lesions and OA has widely increased (Fig. 2), as
confirmed by the growing number of clinical trials
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published on this topic. In addition to an intensive pre-
clinical research, the use of these procedures has re-
cently broken down the barriers towards clinical
application, with more than half of the available papers
published in the last 3 years. Different sources have been
investigated for clinical application, especially targeting
knee or ankle cartilage disease. Among them, the most
exploited cell types are those derived from bone marrow
and adipose tissue. Cells have been used either after cul-
ture expansion or simply concentrated for one-step pro-
cedures: in particular, adipose cells have been applied
mainly through cell concentration, and cells derived
from bone marrow are currently applied both after ex-
pansion or concentration, while PBSCs and SDSCs can
be only exploited through in vitro expansion due to their
low number.
Regardless of cell source and manipulation, cells have
being administered either surgically or through i.a. injec-
tion, to target focal lesions as well as degenerative joint
disease.
Overall, despite the increasing literature on this topic,
there is still limited evidence about the use of MSCs for
the treatment of articular cartilage, in particular as far as
high-level studies are concerned: in fact, most of the
available papers are case series, while only few papers re-
ported RCTs. Moreover, the few high level studies do
not allow to clearly prove the effective potential of
MSCs, due to the limited number of patients treated and
to the presence of several confounding factors (PRP con-
comitant use, cell use in combination with scaffolds,
etc.). To this regard, while several studies applied cells in
association with PRP, with the rationale to provide both
cells and growth factors at the same time, there is no
evidence that adding platelet-derived growth factors pro-
vides any increased benefit with respect to cell adminis-
tration alone, and specifically designed studies are
needed in order to clarify the role of PRP with respect to
MSCs and/or scaffolds in cartilage treatment. Further-
more, the tissue harvest procedure poses practical and
ethical limitations which prevent from performing stud-
ies with a blinded design, therefore leaving an important
bias related to the placebo effect, which is an important
issue in this field of new fashionable regenerative
treatments.
On the other hand, the available studies still allow to
draw some indications on potential and limitations of
MSCs clinical use for the treatment of cartilage lesions
and OA.
First, the use of MSCs in the clinical setting can be
considered safe, since no major adverse events related to
the treatment nor to the cell harvest have been reported,
at least from the available reports at short- to mid-term
follow-up. Second, a clinical benefit of using MSCs ther-
apies has been reported in most of the studies,
regardless of cell source, indication, or administration
method. This effectiveness has been reflected by clinical
improvement but also positive MRI and macroscopic
findings, whereas histologic features gave more contro-
versial results among different studies. Third, different
studies also gave a few indications regarding the patients
who might benefit more from MSCs treatment: young
age, lower BMI, smaller lesion size for focal lesions, and
earlier stages of OA joints have been shown to correlate
with better outcomes, even though the available data
strength does not allow to define clear cutoff values.
The systematic analysis of the literature also allowed
to underline other interesting findings that deserve to be
discussed. Definite trends can be observed with regard
to the delivery method: while different combinations of
products and delivery methods have been investigated
over the years, currently cultured cells are mostly being
administered by i.a. injection, while one-step surgical im-
plantation is preferred for cell concentrates. The differ-
ent trends observed in this field are explained both by
the controversial preclinical and clinical findings, which
still leaves space for clinical investigations in opposite
direction, but also by practical considerations, both in
terms of economical, ethical, and regulatory limitations
[6]. Many aspects are taken in consideration for the
treatment choice, with physicians and researchers ex-
ploring different strategies, each one presenting potential
advantages and possible drawbacks. To this regard, while
culture expansion guarantees a selected MSC lineage to
be delivered, but presenting high costs and some con-
tamination risks related to cell manipulation, cell con-
centration offers a lower number of MSCs, in a
heterogeneous cell population, and can be performed in
one step, thus simplifying the procedure, reducing costs,
and increasing patient compliance. To date, no clear evi-
dence of superior outcome between the two cell manip-
ulations is available, and also their most effective
delivery method remains to be defined, with only a sin-
gle retrospective study reporting better results for surgi-
cal delivery compared to i.a. SVF injection in a matched-
paired analysis of two groups treated for single focal de-
fects in knee OA [75]. Regarding surgical implantation,
the use of solid scaffolds has been shown to be beneficial
for SVF implantation [71], and it is the gold standard for
the application of BMC [37–41, 43, 47, 48, 50, 51]. The
good results obtained with scaffolds implanted with
BMC have been compared with chondrocyte-based sur-
gical techniques, showing similar outcomes, but with the
advantage of the one-step approach [42, 43, 47].
Finally, regardless of cell source, manipulation and de-
livery method, the optimal cell dose is still under investi-
gation. After a first preliminary study reported no
complications related to high dose of cultured ADSCs
[59], only a single clinical study specifically focused on
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this aspect, suggesting benefits and absence of side ef-
fects by using higher dose of BMSCs for the treat-
ment of post-meniscectomized knees [25]. However,
the lack of standardization and the heterogeneity of
the studies reported in the current literature do not
allow to extend these findings to the several proposed
MSCs treatment strategies.
The clinical application of MSCs for the treatment of
articular cartilage defects and OA shows promising re-
sults, but too many questions still remain open. Even
though no complications have been reported, longer
follow-ups on broader patient population are needed to
confirm the safety of these procedures. Likewise, while
promising results have been shown, the potential of
these treatments should be confirmed by reliable clinical
data through double-blind, controlled, prospective, and
multicenter studies with longer follow-up. In addition,
specific studies should be designed to identify the best
cell sources, manipulation, and delivery techniques, as
well as pathology and disease phase indications, with the
aim of optimizing the outcome for a treatment focused
on focal chondral defects or joint degeneration.
Conclusions
This systematic review revealed a high interest of re-
searchers in the clinical use of MSCs for cartilage and
OA treatment, as testified by the increasing number of
reports published over time. Whereas the lack of contra-
indication and generally promising clinical outcomes
have been reported, the prevalence of low-quality stud-
ies, with many variables, shows several aspects that still
need to be optimized, such as the best cell source and
the most appropriate processing method, the most ef-
fective dose and delivery procedure. On the other hand,
the first hints on the kind of patients who might benefit
more from these procedures are being drawn. High-level
studies with large number of patients and long-term
follow-up are mandatory to evaluate the real potential of
this biological approach for cartilage repair.
Abbreviations
ADSCs: mesenchymal stem cells derived from adipose tissue; BMC: bone
marrow concentrate; BMSCs: bone marrow expanded stem cells; FG: fibrin
glue; HA: hyaluronic acid; HTO: high tibial osteotomy; i.a.: intra-articular;
MAST: matrix-assisted stem cells transplantation; MFX: microfractures;
MSCs: mesenchymal stem cells; OA: osteoarthritis; OLK: osteochondral knee
lesion; OLTs: osteochondral lesions of the talus; PBSCs: stem cells derived
from peripheral blood; PEMFs: pulsed electromagnetic fields;
RCT: randomized controlled trial; SDSCs: mesenchymal stem cells derived
from synovial tissue; SVF: stromal vascular fraction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors were involved in the conception and design of the study or
acquisition of data or analysis and interpretation of data and contributed to
drafting the article or revising it critically for important intellectual content.
All authors gave their final approval of the manuscript to be submitted.
Acknowledgements
This project received institutional support by the Italian Ministry of Health
Ricerca Finalizzata (RF-2011-02352638).
Author details
1II Orthopaedic and Traumatologic Clinic, Rizzoli Orthopaedic Institute,
Bologna, Italy. 2Nanobiotechnology Laboratory, Rizzoli Orthopaedic Institute,
Via di Barbiano 1/10, 40136 Bologna, Italy.
Received: 16 February 2016 Accepted: 29 March 2016
References
1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang
MH, Kremers HM, Mayes MD, Merkel PA, et al. Estimates of the prevalence
of arthritis and other rheumatic conditions in the United States. Part I.
Arthritis Rheum. 2008;58:15–25.
2. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden
of osteoarthritis. Br Med Bull. 2013;105:185–99.
3. Di Martino A, Kon E, Perdisa F, Sessa A, Filardo G, Neri MP, Bragonzoni L,
Marcacci M. Surgical treatment of early knee osteoarthritis with a cell-free
osteochondral scaffold: results at 24 months of follow-up. Injury. 2015;46
Suppl 8:S33–8.
4. Kon E, Filardo G, Drobnic M, Madry H, Jelic M, van Dijk N, Della Villa S. Non-
surgical management of early knee osteoarthritis. Knee Surg Sports
Traumatol Arthrosc. 2012;20:436–49.
5. Kon E, Filardo G, Roffi A, Andriolo L, Marcacci M. New trends for knee
cartilage regeneration: from cell-free scaffolds to mesenchymal stem cells.
Curr Rev Musculoskelet Med. 2012;5:236–43.
6. Filardo G, Madry H, Jelic M, Roffi A, Cucchiarini M, Kon E. Mesenchymal
stem cells for the treatment of cartilage lesions: from preclinical findings to
clinical application in orthopaedics. Knee Surg Sports Traumatol Arthrosc.
2013;21:1717–29.
7. Manferdini C, Maumus M, Gabusi E, Piacentini A, Filardo G, Peyrafitte JA,
Jorgensen C, Bourin P, Fleury-Cappellesso S, Facchini A, et al. Adipose-
derived mesenchymal stem cells exert antiinflammatory effects on
chondrocytes and synoviocytes from osteoarthritis patients through
prostaglandin E2. Arthritis Rheum. 2013;65:1271–81.
8. Caplan AI. All MSCs are pericytes? Cell Stem Cell. 2008;3:229–30.
9. Caplan AI. New era of cell-based orthopedic therapies. Tissue Eng Part B
Rev. 2009;15:195–200.
10. Perdisa F, Gostynska N, Roffi A, Filardo G, Marcacci M, Kon E. Adipose-
derived mesenchymal stem cells for the treatment of articular cartilage:
a systematic review on preclinical and clinical evidence. Stem Cells Int.
2015;2015:597652.
11. Ahmed TA, Hincke MT. Mesenchymal stem cell-based tissue engineering
strategies for repair of articular cartilage. Histol Histopathol. 2014;29:669–89.
12. Berg L, Koch T, Heerkens T, Bessonov K, Thomsen P, Betts D. Chondrogenic
potential of mesenchymal stromal cells derived from equine bone marrow
and umbilical cord blood. Vet Comp Orthop Traumatol. 2009;22:363–70.
13. Kotobuki N, Hirose M, Takakura Y, Ohgushi H. Cultured autologous human
cells for hard tissue regeneration: preparation and characterization of
mesenchymal stem cells from bone marrow. Artif Organs. 2004;28:33–9.
14. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R.
Mesenchymal stem cells for clinical application. Vox Sang. 2010;98:93–107.
15. Indrawattana N, Chen G, Tadokoro M, Shann LH, Ohgushi H, Tateishi T,
Tanaka J, Bunyaratvej A. Growth factor combination for chondrogenic
induction from human mesenchymal stem cell. Biochem Biophys Res
Commun. 2004;320:914–9.
16. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee
cartilage volume in degenerative joint disease using percutaneously implanted,
autologous mesenchymal stem cells. Pain Physician. 2008;11:343–53.
17. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal
stem cell therapy for knee osteoarthritis. Preliminary report of four patients.
Int J Rheum Dis. 2011;14:211–5.
18. Emadedin M, Aghdami N, Taghiyar L, Fazeli R, Moghadasali R, Jahangir S,
Farjad R, Baghaban Eslaminejad M. Intra-articular injection of autologous
mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran
Med. 2012;15:422–8.
19. Rich S, Munar A, Soler Romagosa F, Peirau X, Huguet M, Alberca M, Sánchez
A, García Sancho J, Orozco L. Treatment of knee osteoarthritis with
Filardo et al. Journal of Orthopaedic Surgery and Research  (2016) 11:42 Page 13 of 15
autologous expanded bone marrow mesenchymal stem cells: 50 cases
clinical and MRI results at one year follow-up. J Stem Cell Res Ther. 2015;5:7.
20. Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentis J, Sanchez
A, Garcia-Sancho J. Treatment of knee osteoarthritis with autologous
mesenchymal stem cells: a pilot study. Transplantation. 2013;95:1535–41.
21. Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentis J, Sanchez
A, Garcia-Sancho J. Treatment of knee osteoarthritis with autologous
mesenchymal stem cells: two-year follow-up results. Transplantation. 2014;
97:e66–8.
22. Davatchi F, Sadeghi Abdollahi B, Mohyeddin M, Nikbin B. Mesenchymal
stem cell therapy for knee osteoarthritis: 5 years follow-up of three patients.
Int J Rheum Dis. 2015.
23. Lee KB, Wang VT, Chan YH, Hui JH. A novel, minimally-invasive technique of
cartilage repair in the human knee using arthroscopic microfracture and
injections of mesenchymal stem cells and hyaluronic acid—a prospective
comparative study on safety and short-term efficacy. Ann Acad Med
Singapore. 2012;41:511–7.
24. Wong KL, Lee KB, Tai BC, Law P, Lee EH, Hui JH. Injectable cultured bone
marrow-derived mesenchymal stem cells in varus knees with cartilage
defects undergoing high tibial osteotomy: a prospective, randomized
controlled clinical trial with 2 years’ follow-up. Arthroscopy. 2013;29:2020–8.
25. Vangsness Jr CT, Farr 2nd J, Boyd J, Dellaero DT, Mills CR, LeRoux-Williams
M. Adult human mesenchymal stem cells delivered via intra-articular
injection to the knee following partial medial meniscectomy: a randomized,
double-blind, controlled study. J Bone Joint Surg Am. 2014;96:90–8.
26. Vega A, Martin-Ferrero MA, Del Canto F, Alberca M, Garcia V, Munar A,
Orozco L, Soler R, Fuertes JJ, Huguet M, et al. Treatment of knee
osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a
randomized controlled trial. Transplantation. 2015;99:1681–90.
27. Adachi N, Ochi M, Deie M, Ito Y. Transplant of mesenchymal stem cells and
hydroxyapatite ceramics to treat severe osteochondral damage after septic
arthritis of the knee. J Rheumatol. 2005;32:1615–8.
28. Haleem AM, Singergy AA, Sabry D, Atta HM, Rashed LA, Chu CR, El Shewy
MT, Azzam A, Abdel Aziz MT. The clinical use of human culture-expanded
autologous bone marrow mesenchymal stem cells transplanted on platelet-
rich fibrin glue in the treatment of articular cartilage defects: a pilot study
and preliminary results. Cartilage. 2010;1:253–61.
29. Kasemkijwattana C, Hongeng S, Kesprayura S, Rungsinaporn V, Chaipinyo K,
Chansiri K. Autologous bone marrow mesenchymal stem cells implantation
for cartilage defects: two cases report. J Med Assoc Thai. 2011;94:395–400.
30. Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, Ohgushi H,
Wakitani S, Kurosaka M. Treatment of a full-thickness articular cartilage
defect in the femoral condyle of an athlete with autologous bone-marrow
stromal cells. Osteoarthritis Cartilage. 2007;15:226–31.
31. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H. Repair of
articular cartilage defects in the patello-femoral joint with autologous bone
marrow mesenchymal cell transplantation: three case reports involving nine
defects in five knees. J Tissue Eng Regen Med. 2007;1:74–9.
32. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S.
Autologous bone marrow stromal cell transplantation for repair of full-
thickness articular cartilage defects in human patellae: two case reports. Cell
Transplant. 2004;13:595–600.
33. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human
autologous culture expanded bone marrow mesenchymal cell
transplantation for repair of cartilage defects in osteoarthritic knees.
Osteoarthritis Cartilage. 2002;10:199–206.
34. Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH. Autologous bone
marrow-derived mesenchymal stem cells versus autologous
chondrocyte implantation: an observational cohort study. Am J Sports
Med. 2010;38:1110–6.
35. Richter M, Zech S. Matrix-associated stem cell transplantation (MAST) in
chondral defects of foot and ankle is effective. Foot Ankle Surg. 2013;19:84–90.
36. Varma HS, Dadarya B, Vidyarthi A. The new avenues in the management of
osteo-arthritis of knee—stem cells. J Indian Med Assoc. 2010;108:583–5.
37. Giannini S, Buda R, Vannini F, Cavallo M, Grigolo B. One-step bone marrow-
derived cell transplantation in talar osteochondral lesions. Clin Orthop Relat
Res. 2009;467:3307–20.
38. Giannini S, Buda R, Battaglia M, Cavallo M, Ruffilli A, Ramponi L, Pagliazzi G,
Vannini F. One-step repair in talar osteochondral lesions: 4-year clinical
results and t2-mapping capability in outcome prediction. Am J Sports Med.
2013;41:511–8.
39. Buda R, Cavallo M, Castagnini F, Cenacchi A, Natali S, Vannini F, Giannini S.
Treatment of hemophilic ankle arthropathy with one-step arthroscopic
bone marrow-derived cells transplantation. Cartilage. 2015;6:150–5.
40. Buda R, Castagnini F, Cavallo M, Ramponi L, Vannini F, Giannini S. “One-
step” bone marrow-derived cells transplantation and joint debridement for
osteochondral lesions of the talus in ankle osteoarthritis: clinical and
radiological outcomes at 36 months. Arch Orthop Trauma Surg. 2015.
41. Buda R, Vannini F, Cavallo M, Baldassarri M, Natali S, Castagnini F,
Giannini S. One-step bone marrow-derived cell transplantation in
talarosteochondral lesions: mid-term results. Joints. 2013;1:102–7.
42. Giannini S, Buda R, Cavallo M, Ruffilli A, Cenacchi A, Cavallo C, Vannini F.
Cartilage repair evolution in post-traumatic osteochondral lesions of the
talus: from open field autologous chondrocyte to bone-marrow-derived
cells transplantation. Injury. 2010;41:1196–203.
43. Buda R, Vannini F, Castagnini F, Cavallo M, Ruffilli A, Ramponi L, Pagliazzi G,
Giannini S. Regenerative treatment in osteochondral lesions of the talus:
autologous chondrocyte implantation versus one-step bone marrow
derived cells transplantation. Int Orthop. 2015;39:893–900.
44. Cadossi M, Buda RE, Ramponi L, Sambri A, Natali S, Giannini S. Bone
marrow-derived cells and biophysical stimulation for talar osteochondral
lesions: a randomized controlled study. Foot Ankle Int. 2014;35:981–7.
45. Buda R, Vannini F, Cavallo M, Grigolo B, Cenacchi A, Giannini S.
Osteochondral lesions of the knee: a new one-step repair technique with
bone-marrow-derived cells. J Bone Joint Surg Am. 2010;92 Suppl 2:2–11.
46. Buda R, Vannini F, Cavallo M, Baldassarri M, Luciani D, Mazzotti A, Pungetti
C, Olivieri A, Giannini S. One-step arthroscopic technique for the treatment
of osteochondral lesions of the knee with bone-marrow-derived cells: three
years results. Musculoskelet Surg. 2013;97:145–51.
47. Gobbi A, Chaurasia S, Karnatzikos G, Nakamura N. Matrix-induced
autologous chondrocyte implantation versus multipotent stem cells for the
treatment of large patellofemoral chondral lesions: a nonrandomized
prospective trial. Cartilage. 2015;6:82–97.
48. Gigante A, Cecconi S, Calcagno S, Busilacchi A, Enea D. Arthroscopic knee
cartilage repair with covered microfracture and bone marrow concentrate.
Arthrosc Tech. 2012;1:e175–80.
49. Gigante A, Calcagno S, Cecconi S, Ramazzotti D, Manzotti S, Enea D. Use of
collagen scaffold and autologous bone marrow concentrate as a one-step
cartilage repair in the knee: histological results of second-look biopsies at 1
year follow-up. Int J Immunopathol Pharmacol. 2011;24:69–72.
50. Gobbi A, Karnatzikos G, Sankineani SR. One-step surgery with multipotent
stem cells for the treatment of large full-thickness chondral defects of the
knee. Am J Sports Med. 2014;42:648–57.
51. Skowronski J, Skowronski R, Rutka M. Large cartilage lesions of the knee
treated with bone marrow concentrate and collagen membrane—results.
Ortop Traumatol Rehabil. 2013;15:69–76.
52. Saw KY, Anz A, Merican S, Tay YG, Ragavanaidu K, Jee CS, McGuire DA.
Articular cartilage regeneration with autologous peripheral blood
progenitor cells and hyaluronic acid after arthroscopic subchondral drilling:
a report of 5 cases with histology. Arthroscopy. 2011;27:493–506.
53. Turajane T, Chaweewannakorn U, Larbpaiboonpong V, Aojanepong J,
Thitiset T, Honsawek S, Fongsarun J, Papadopoulos KI. Combination of intra-
articular autologous activated peripheral blood stem cells with growth
factor addition/ preservation and hyaluronic acid in conjunction with
arthroscopic microdrilling mesenchymal cell stimulation Improves quality of
life and regenerates articular cartilage in early osteoarthritic knee disease. J
Med Assoc Thai. 2013;96:580–8.
54. Saw KY, Anz A, Siew-Yoke Jee C, Merican S, Ching-Soong Ng R, Roohi SA,
Ragavanaidu K. Articular cartilage regeneration with autologous peripheral
blood stem cells versus hyaluronic acid: a randomized controlled trial.
Arthroscopy. 2013;29:684–94.
55. Fu WL, Ao YF, Ke XY, Zheng ZZ, Gong X, Jiang D, Yu JK. Repair of large full-
thickness cartilage defect by activating endogenous peripheral blood stem
cells and autologous periosteum flap transplantation combined with
patellofemoral realignment. Knee. 2014;21:609–12.
56. Skowronski J, Skowronski R, Rutka M. Cartilage lesions of the knee treated
with blood mesenchymal stem cells—results. Ortop Traumatol Rehabil.
2012;14:569–77.
57. Koga H, Muneta T, Nagase T, Nimura A, Ju YJ, Mochizuki T, Sekiya I.
Comparison of mesenchymal tissues-derived stem cells for in vivo
chondrogenesis: suitable conditions for cell therapy of cartilage defects
in rabbit. Cell Tissue Res. 2008;333:207–15.
Filardo et al. Journal of Orthopaedic Surgery and Research  (2016) 11:42 Page 14 of 15
58. Jang Y, Koh YG, Choi YJ, Kim SH, Yoon DS, Lee M, Lee JW.
Characterization of adipose tissue-derived stromal vascular fraction for
clinical application to cartilage regeneration. In Vitro Cell Dev Biol
Anim. 2015;51:142–50.
59. Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, Kim JE, Shim H, Shin JS,
Shin IS, et al. Intra-articular injection of mesenchymal stem cells for the
treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem
Cells. 2014;32:1254–66.
60. Pak J. Regeneration of human bones in hip osteonecrosis and human
cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem
cells: a case series. J Med Case Rep. 2011;5:296.
61. Pak J, Chang JJ, Lee JH, Lee SH. Safety reporting on implantation of
autologous adipose tissue-derived stem cells with platelet-rich plasma into
human articular joints. BMC Musculoskelet Disord. 2013;14:337.
62. Bui K, Duong T, Nguyen N, Nguyen T, Le V, Thanh Mai V, Lu-Chinh
Phan N, Le Minh D, Ngoc N, Van Pham P. Symptomatic knee
osteoarthritis treatment using autologous adipose derived stem cells
and platelet-rich plasma: a clinical study. Biomedical Research and
Therapy. 2014;1:02–8.
63. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell
therapy for knee osteoarthritis. Knee. 2012;19:902–7.
64. Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ. Mesenchymal
stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy.
2013;29:748–55.
65. Koh YG, Choi YJ, Kwon SK, Kim YS, Yeo JE. Clinical results and second-look
arthroscopic findings after treatment with adipose-derived stem cells for
knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2015;23:1308–16.
66. Koh YG, Kwon OR, Kim YS, Choi YJ. Comparative outcomes of open-wedge
high tibial osteotomy with platelet-rich plasma alone or in combination
with mesenchymal stem cell treatment: a prospective study. Arthroscopy.
2014;30:1453–60.
67. Michalek J, Moster R, Lukac L, Proefrock K, Petrasovic M, Rybar J, et al.
Autologous adipose tissue-derived stromal vascular fraction cells application
in patients with osteoarthritis. Cell Transplant. 2015.
68. Kim YS, Park EH, Kim YC, Koh YG. Clinical outcomes of mesenchymal stem
cell injection with arthroscopic treatment in older patients with
osteochondral lesions of the talus. Am J Sports Med. 2013;41:1090–9.
69. Kim YS, Lee HJ, Choi YJ, Kim YI, Koh YG. Does an injection of a stromal
vascular fraction containing adipose-derived mesenchymal stem cells
influence the outcomes of marrow stimulation in osteochondral lesions of
the talus? A clinical and magnetic resonance imaging study. Am J Sports
Med. 2014;42:2424–34.
70. Koh YG, Choi YJ, Kwon OR, Kim YS. Second-look arthroscopic evaluation of
cartilage lesions after mesenchymal stem cell implantation in osteoarthritic
knees. Am J Sports Med. 2014;42:1628–37.
71. Kim YS, Choi YJ, Suh DS, Heo DB, Kim YI, Ryu JS, Koh YG. Mesenchymal
stem cell implantation in osteoarthritic knees: is fibrin glue effective as a
scaffold? Am J Sports Med. 2015;43:176–85.
72. Kim YS, Choi YJ, Lee SW, Kwon OR, Suh DS, Heo DB, Koh YG. Assessment of
clinical and MRI outcomes after mesenchymal stem cell implantation in
patients with knee osteoarthritis: a prospective study. Osteoarthritis
Cartilage. 2016;24:237–45.
73. Kim YS, Choi YJ, Koh YG. Mesenchymal stem cell implantation in knee
osteoarthritis: an assessment of the factors influencing clinical outcomes.
Am J Sports Med. 2015;43:2293–301.
74. Koh YG, Kwon OR, Kim YS, Choi YJ, Tak DH. Adipose-derived mesenchymal
stem cells with microfracture versus microfracture alone: 2-year follow-up of
a prospective randomized trial. Arthroscopy. 2016;32:97–109.
75. Kim YS, Kwon OR, Choi YJ, Suh DS, Heo DB, Koh YG. Comparative matched-
pair analysis of the injection versus implantation of mesenchymal stem cells
for knee osteoarthritis. Am J Sports Med. 2015;43:2738–46.
76. Sekiya I, Muneta T, Horie M, Koga H. Arthroscopic transplantation of synovial
stem cells improves clinical outcomes in knees with cartilage defects. Clin
Orthop Relat Res. 2015;473:2316–26.
77. Skowronski J, Rutka M. Osteochondral lesions of the knee reconstructed with
mesenchymal stem cells—results. Ortop Traumatol Rehabil. 2013;15:195–204.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Filardo et al. Journal of Orthopaedic Surgery and Research  (2016) 11:42 Page 15 of 15
